ArticleAntimicrobial agents and chemotherapy2013
A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 3 syntheses or guidelines pooled it, 136 citations in OpenAlex.
- Data-driven Atlas ofFrontiers in cellular and infection microbiology · 2026Pooled it
- Unveiling the role of adhesin proteins in controllingInfection and immunity · 2025Pooled it
- Urinary tract colonization is enhanced by a plasmid that regulates uropathogenic Acinetobacter baumannii chromosomal genes.Nature communications · 2019Pooled it
- Complete genome of multiply antibiotic resistant ST10Microbiology spectrum · 2026Article
- Structural insights and therapeutic targets in Acinetobacter baumannii capsule biosynthesis.FEBS letters · 2026Article
- Article
- A non-antibiotic genetic selection system enables near-infrared in vivo imaging and evaluation of antibiotic efficacy for multidrug-resistant Acinetobacter baumannii.The Journal of antibiotics · 2026Article
- A Clinically Silent Resistance Phenotype That PromotesbioRxiv : the preprint server for biology · 2026Article
- Resistance, heteroresistance, and fitness costs drive colistin treatment failure duringProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Peptide-based antimicrobial effect against carbapenem-resistantFrontiers in pharmacology · 2026Article
- Regulation of drug resistance and virulence ofFrontiers in microbiology · 2026Article
- Emerging virulent clones of community-onset Acinetobacter baumannii in Taiwan.Tropical medicine and health · 2025Article
- Sepsis-induced inflammasome impairment facilitates development of secondaryEmerging microbes & infections · 2025Article
- Resistance, heteroresistance and fitness costs drive colistin treatment failure duringbioRxiv : the preprint server for biology · 2025Article
- Gene dependence during mammalianMicrobial genomics · 2025Article
- HypervirulentAntibiotics (Basel, Switzerland) · 2025Review
- Secondary bacterial infections of Carbapenem-Resistant Acinetobacter baumannii in patients with COVID-19 admitted to Chinese ICUs.BMC microbiology · 2025Article
- Recent advances in host models in studying virulence factors and pathogenesis ofFrontiers in cellular and infection microbiology · 2025Review
- Nano-Emulsion Incorporating Squalene and MnInternational journal of nanomedicine · 2025Article
- Humoral response induced after intranasal vaccination with heat inactivatedFrontiers in immunology · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acinetobacter baumannii is an important emerging pathogen in health care-acquired infections and is responsible for severe nosocomial and community-acquired pneumonia. Currently available mouse models of A. baumannii pneumonia show poor colonization with little to no extrapulmonary dissemination. Here, we describe a mouse model of A. baumannii pneumonia using a clinical isolate (LAC-4 strain) that reliably reproduces the most relevant features of human pulmonary A. baumannii infection and pathology. Using this model, we have shown that LAC-4 infection induced rapid bacterial replication in the lungs, significant extrapulmonary dissemination, and severe bacteremia by 24 h postintranasal inoculation. Infected mice showed severe bronchopneumonia and dilatation and inflammatory cell infiltration in the perivascular space. More significantly, 100% of C57BL/6 and BALB/c mice succumbed to 10(8) CFU of LAC-4 inoculation within 48 h. When this model was used to assess the efficacy of antimicrobials, all mice treated with imipenem and tigecycline survived a lethal intranasal challenge, with minimal clinical signs and body weight loss. Moreover, intranasal immunization of mice with formalin-fixed LAC-4 protected 40% of mice from a lethal (100× 100% lethal dose) intraperitoneal challenge. Thus, this model offers a reproducible acute course of A. baumannii pneumonia without requiring additional manipulation of host immune status, which will facilitate the development of therapeutic agents and vaccines against A. baumannii pneumonia in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.